Conmed price target lowered to $55 from $68 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Conmed (CNMD) to $55 from $68 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that were roughly in-line with its estimates on the top-and-bottom line. Management essentially kept its revenue guidance for the year unchanged but did lower EPS by three cents, Piper adds.